Home › Rhabdomyosarcoma › Massachusetts › Boston
Rhabdomyosarcoma clinical trials in Boston, MA
4 studies for Rhabdomyosarcoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RecruitingPhase 3
- Dana-Farber Cancer Institute, Boston
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPhase 1/2
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
RecruitingPhase 1/2
- Boston Children's Hospital, Boston
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RecruitingPhase 1/2
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Rhabdomyosarcoma trials in other cities
- Houston, TX6 studies
- Memphis, TN6 studies
- Washington, DC5 studies
- Salt Lake City, UT4 studies
- Philadelphia, PA4 studies
- Seattle, WA3 studies
- Aurora, CO3 studies
- Dallas, TX3 studies
- Birmingham, AL3 studies
- The Bronx, NY3 studies
- Baltimore, MD3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.